Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic
receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides
faster, greater, and more consistent P2Y12 inhibition than Clopidogrel in patients with acute
coronary syndrome, irrespective of the genetic variants affecting Clopidogrel metabolism. It
is still undefined whether combination therapy of Ticagrelor and Aspirin is more effective
than Clopidogrel and aspirin for minor stroke and transient ischemic attack (TIA). The
primary purpose of the PRINCE trial is to evaluate the anti-platelet effects of a 3-month
regimen of ticagrelor initiated with 180 mg loading dose followed by 90 mg twice/day combined
with aspirin 100 mg/day during first 21 days versus a 3-month regimen of clopidogrel
initiated with 300 mg loading dose of followed by 75 mg/day combined with aspirin 100 mg/day
during first 21 days when initiated within 24 hours of symptom onset in high-risk transient
ischemic attack or minor stroke.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Beijing Tiantan Hospital Ministry of Science and Technology of the People´s Republic of China